Remove 2025 Remove Diabetes Remove Kidney Disease
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25

article thumbnail

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). Accessed February 21, 2025. Accessed March 5, 2025. Accessed February 21, 2025.

article thumbnail

Pay attention to 4 health factors to prevent new heart syndrome

American Heart News - Heart News

18, 2025 About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidney disease, type 2 diabetes and obesity.[1] DALLAS, Feb. 1] This cluster of chronic health conditions is called.

article thumbnail

Top 5 FDA Approvals from Q1 2025

HCPLive

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

article thumbnail

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review

Circulation

Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors.

article thumbnail

Top 10 AI Cardiometabolic Startups to Watch in 2025 

Cardiometabolic Health Congress

This exciting overview highlights the top 10 AI-powered cardiometabolic startups poised to make significant impacts in 2025. Vitadio : Digital therapeutics for type 2 diabetes and prediabetes, expanding globally. LumineticsCore : An AI diagnostics company with FDA-cleared systems for detecting diabetic retinopathy.

article thumbnail

Your Top Five Questions About CMHC On-Demand, Answered

Cardiometabolic Health Congress

On-demand access is available now and will remain open until December 2025. Diabetes Management: Gain insights into precision medicine, advanced insulin therapies, and continuous glucose monitoring (CGM) for cardiovascular risk assessment. When Will It Be Available?

CME 52